Vical plans to price public offering of common stock with greenshoe

Citigroup, Credit Suisse, Leerink Swann, Rodman & Renshaw assist

By Devika Patel

Knoxville, Tenn., Jan. 5 - Vical Inc. will price a public offering of common stock, according to a prospectus supplement filed Thursday with the Securities and Exchange Commission. The deal will have a 30-day greenshoe.

Citigroup Global Markets Inc., Credit Suisse Securities (USA) LLC and Leerink Swann LLC are the joint bookrunning managers; Rodman & Renshaw, LLC is the co-manager.

Proceeds will be used for general corporate purposes.

Vical, based in San Diego, develops DNA-based vaccines for infectious diseases and cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.